Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1227

1.

A preclinical overview of emerging therapeutic targets for glomerular diseases.

Cassis P, Zoja C, Perico L, Remuzzi G.

Expert Opin Ther Targets. 2019 Jul;23(7):593-606. doi: 10.1080/14728222.2019.1626827. Epub 2019 Jun 12.

PMID:
31150308
2.

Engineering the vasculature of decellularized rat kidney scaffolds using human induced pluripotent stem cell-derived endothelial cells.

Ciampi O, Bonandrini B, Derosas M, Conti S, Rizzo P, Benedetti V, Figliuzzi M, Remuzzi A, Benigni A, Remuzzi G, Tomasoni S.

Sci Rep. 2019 May 29;9(1):8001. doi: 10.1038/s41598-019-44393-y.

3.

[Drugs for rare diseases: the blessing of being orphans.]

Costa E, Schieppati A, Luzzatto L, Remuzzi G.

Recenti Prog Med. 2019 May;110(5):221-229. doi: 10.1701/3163.31444. Italian.

PMID:
31140454
4.

Rare Functional Variants in Complement Genes and Anti-FH Autoantibodies-Associated aHUS.

Valoti E, Alberti M, Iatropoulos P, Piras R, Mele C, Breno M, Cremaschi A, Bresin E, Donadelli R, Alizzi S, Amoroso A, Benigni A, Remuzzi G, Noris M.

Front Immunol. 2019 May 1;10:853. doi: 10.3389/fimmu.2019.00853. eCollection 2019.

5.

Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial.

Ruggiero B, Trillini M, Tartaglione L, Rotondi S, Perticucci E, Tripepi R, Aparicio C, Lecchi V, Perna A, Peraro F, Villa D, Ferrari S, Cannata A, Mazzaferro S, Mallamaci F, Zoccali C, Bellasi A, Cozzolino M, Remuzzi G, Ruggenenti P, Kohan DE; ANSWER Study Organization.

Am J Kidney Dis. 2019 Apr 23. pii: S0272-6386(19)30136-2. doi: 10.1053/j.ajkd.2019.01.029. [Epub ahead of print]

PMID:
31027883
6.

Orphan drugs - Authors' reply.

Luzzatto L, Costa E, Schieppati A, Remuzzi G.

Lancet. 2019 Apr 20;393(10181):1595-1596. doi: 10.1016/S0140-6736(19)30014-5. No abstract available.

PMID:
31007199
7.

CRISPR-Cas9-Mediated Correction of the G189R-PAX2 Mutation in Induced Pluripotent Stem Cells from a Patient with Focal Segmental Glomerulosclerosis.

Trionfini P, Ciampi O, Todeschini M, Ascanelli C, Longaretti L, Perico L, Remuzzi G, Benigni A, Tomasoni S.

CRISPR J. 2019 Apr;2:108-120. doi: 10.1089/crispr.2018.0048.

PMID:
30998089
8.

Why and how did Leonardo happen: the Renaissance context.

Remuzzi G, Ricciardi W.

Lancet. 2019 Apr 6;393(10179):1396-1397. doi: 10.1016/S0140-6736(19)30548-3. Epub 2019 Apr 4. No abstract available.

PMID:
30967202
9.

Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial.

Perico N, Ruggenenti P, Perna A, Caroli A, Trillini M, Sironi S, Pisani A, Riccio E, Imbriaco M, Dugo M, Morana G, Granata A, Figuera M, Gaspari F, Carrara F, Rubis N, Villa A, Gamba S, Prandini S, Cortinovis M, Remuzzi A, Remuzzi G; ALADIN 2 Study Group.

PLoS Med. 2019 Apr 5;16(4):e1002777. doi: 10.1371/journal.pmed.1002777. eCollection 2019 Apr.

10.

C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial.

Ruggenenti P, Daina E, Gennarini A, Carrara C, Gamba S, Noris M, Rubis N, Peraro F, Gaspari F, Pasini A, Rigotti A, Lerchner RM, Santoro D, Pisani A, Pasi A, Remuzzi G; EAGLE Study Group.

Am J Kidney Dis. 2019 Mar 28. pii: S0272-6386(19)30100-3. doi: 10.1053/j.ajkd.2018.12.046. [Epub ahead of print]

PMID:
30929851
11.

Hemolytic Uremic Syndrome in an Infant with Primary Hyperoxaluria Type II: An Unreported Clinical Association.

Valoti E, Alberti M, Carrara C, Breno M, Yilmaz Keskin E, Bresin E, Cuccarolo P, Açikgöz Y, Benigni A, Noris M, Remuzzi G, Mele C.

Nephron. 2019 Mar 19:1-7. doi: 10.1159/000497823. [Epub ahead of print]

PMID:
30889567
12.

An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome.

Galbusera M, Noris M, Gastoldi S, Bresin E, Mele C, Breno M, Cuccarolo P, Alberti M, Valoti E, Piras R, Donadelli R, Vivarelli M, Murer L, Pecoraro C, Ferrari E, Perna A, Benigni A, Portalupi V, Remuzzi G.

Am J Kidney Dis. 2019 Mar 6. pii: S0272-6386(19)30003-4. doi: 10.1053/j.ajkd.2018.11.012. [Epub ahead of print]

PMID:
30851964
13.

Disaster medicine and response: Optimizing life-saving potential.

Sever MS, Remuzzi G, Vanholder R.

Am J Disaster Med. 2018 Fall;13(4):253-264. doi: 10.5055/ajdm.2018.0305. Review.

PMID:
30821339
14.

Effect of Timing and Complement Receptor Antagonism on Intragraft Recruitment and Pro-Tolerogenic Effects of Mesenchymal Stromal Cells in Murine Kidney Transplantation.

Casiraghi F, Todeschini M, Azzollini N, Cravedi P, Cassis P, Solini S, Fiori S, Rota C, Karachi A, Carrara C, Noris M, Perico N, Remuzzi G.

Transplantation. 2019 Feb 18. doi: 10.1097/TP.0000000000002611. [Epub ahead of print]

PMID:
30801518
15.

Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial.

Ruggenenti P, Trillini M, P Barlovic D, Cortinovis M, Pisani A, Parvanova A, Iliev IP, Ruggiero B, Rota S, Aparicio MC, Perna A, Peraro F, Diadei O, Gaspari F, Carrara F, Stucchi N, Martinetti D, Janez A, Gregoric N, Riccio E, Bossi AC, Trevisan R, Manunta P, Battaglia G, David S, Aucella F, Belviso A, Satta A, Remuzzi G; VALID Study Organization.

Diabetes Obes Metab. 2019 May;21(5):1177-1190. doi: 10.1111/dom.13639. Epub 2019 Feb 22.

PMID:
30793466
16.

Urinary proteome signature of Renal Cysts and Diabetes syndrome in children.

Ricci P, Magalhães P, Krochmal M, Pejchinovski M, Daina E, Caruso MR, Goea L, Belczacka I, Remuzzi G, Umbhauer M, Drube J, Pape L, Mischak H, Decramer S, Schaefer F, Schanstra JP, Cereghini S, Zürbig P.

Sci Rep. 2019 Feb 18;9(1):2225. doi: 10.1038/s41598-019-38713-5.

17.

C3 glomerulopathy - understanding a rare complement-driven renal disease.

Smith RJH, Appel GB, Blom AM, Cook HT, D'Agati VD, Fakhouri F, Fremeaux-Bacchi V, Józsi M, Kavanagh D, Lambris JD, Noris M, Pickering MC, Remuzzi G, de Córdoba SR, Sethi S, Van der Vlag J, Zipfel PF, Nester CM.

Nat Rev Nephrol. 2019 Mar;15(3):129-143. doi: 10.1038/s41581-018-0107-2. Review.

PMID:
30692664
18.

Albuminuria Regression in Diabetes: A Therapeutic Target for Nephro- and Cardio-Protection, in Clinics and Research.

Ruggenenti P, Remuzzi G.

Am J Nephrol. 2019;49(2):143-145. doi: 10.1159/000496275. Epub 2019 Jan 24. No abstract available.

19.

Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease.

Charytan DM, Solomon SD, Ivanovich P, Remuzzi G, Cooper ME, McGill JB, Parving HH, Parfrey P, Singh AK, Burdmann EA, Levey AS, Eckardt KU, McMurray JJV, Weinrauch LA, Liu J, Claggett B, Lewis EF, Pfeffer MA.

Diabetes Obes Metab. 2019 May;21(5):1199-1208. doi: 10.1111/dom.13642. Epub 2019 Mar 4.

PMID:
30672083
20.

Complement Activation Contributes to the Pathophysiology of Shiga Toxin-Associated Hemolytic Uremic Syndrome.

Buelli S, Zoja C, Remuzzi G, Morigi M.

Microorganisms. 2019 Jan 10;7(1). pii: E15. doi: 10.3390/microorganisms7010015. Review.

21.

Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).

Mc Causland FR, Claggett B, Burdmann EA, Chertow GM, Cooper ME, Eckardt KU, Ivanovich P, Levey AS, Lewis EF, McGill JB, McMurray JJV, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto RD, Pfeffer MA.

Am J Kidney Dis. 2019 Mar;73(3):309-315. doi: 10.1053/j.ajkd.2018.10.006. Epub 2018 Dec 19.

PMID:
30578152
22.

Author Correction: Estimated GFR: time for a critical appraisal.

Porrini E, Ruggenenti P, Luis-Lima S, Carrara F, Jiménez A, de Vries APJ, Torres A, Gaspari F, Remuzzi G.

Nat Rev Nephrol. 2019 Feb;15(2):121. doi: 10.1038/s41581-018-0105-4.

PMID:
30563967
23.

Data on the assessment of LV mechanics by speckle tracking echocardiography in ADPKD patients.

Spinelli L, Pisani A, Giugliano G, Trimarco B, Riccio E, Visciano B, Remuzzi G, Ruggenenti P.

Data Brief. 2018 Nov 14;21:2075-2081. doi: 10.1016/j.dib.2018.11.041. eCollection 2018 Dec.

24.

Estimated GFR: time for a critical appraisal.

Porrini E, Ruggenenti P, Luis-Lima S, Carrara F, Jiménez A, de Vries APJ, Torres A, Gaspari F, Remuzzi G.

Nat Rev Nephrol. 2019 Mar;15(3):177-190. doi: 10.1038/s41581-018-0080-9. Review. Erratum in: Nat Rev Nephrol. 2018 Dec 18;:.

PMID:
30518813
25.

Left ventricular dysfunction in ADPKD and effects of octreotide-LAR: A cross-sectional and longitudinal substudy of the ALADIN trial.

Spinelli L, Pisani A, Giugliano G, Trimarco B, Riccio E, Visciano B, Remuzzi G, Ruggenenti P; ALADIN-Cardiovascular Study Group.

Int J Cardiol. 2019 Jan 15;275:145-151. doi: 10.1016/j.ijcard.2018.10.063. Epub 2018 Oct 22.

PMID:
30509370
26.

Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.

Donadelli R, Pulieri P, Piras R, Iatropoulos P, Valoti E, Benigni A, Remuzzi G, Noris M.

Front Immunol. 2018 Oct 15;9:2329. doi: 10.3389/fimmu.2018.02329. eCollection 2018.

27.

A comparison of metrics and performance characteristics of different search strategies for article retrieval for a systematic review of the global epidemiology of kidney and urinary diseases.

Bikbov B, Perico N, Remuzzi G; GBD Genitourinary Diseases Expert Group.

BMC Med Res Methodol. 2018 Oct 19;18(1):110. doi: 10.1186/s12874-018-0569-8.

28.

Mesenchymal stromal cells in kidney transplantation.

Casiraghi F, Remuzzi G.

Curr Opin Nephrol Hypertens. 2019 Jan;28(1):40-46. doi: 10.1097/MNH.0000000000000461.

PMID:
30300159
29.

Maternal and environmental risk factors for neonatal AKI and its long-term consequences.

Perico N, Askenazi D, Cortinovis M, Remuzzi G.

Nat Rev Nephrol. 2018 Nov;14(11):688-703. doi: 10.1038/s41581-018-0054-y. Review.

PMID:
30224767
30.

Kidney Disease.

Anand S, Thomas B, Remuzzi G, Riella M, Nahas ME, Naicker S, Dirks J.

In: Prabhakaran D, Anand S, Gaziano TA, Mbanya JC, Wu Y, Nugent R, editors. Cardiovascular, Respiratory, and Related Disorders. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 17. Chapter 13.

31.

Addressing acute kidney injury in critically ill newborn babies.

Perico N, Remuzzi G.

Lancet Child Adolesc Health. 2017 Nov;1(3):161-163. doi: 10.1016/S2352-4642(17)30071-8. Epub 2017 Sep 8. No abstract available.

PMID:
30169159
32.

Prognosis and determinants of serum PTH changes over time in 1-5 CKD stage patients followed in tertiary care.

Borrelli S, Chiodini P, De Nicola L, Minutolo R, Provenzano M, Garofalo C, Remuzzi G, Ronco C, Cozzolino MG, Manno C, Costanzo AM, Gualberti G, Conte G.

PLoS One. 2018 Aug 23;13(8):e0202417. doi: 10.1371/journal.pone.0202417. eCollection 2018.

33.

Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMA.

Selby NM, Blankestijn PJ, Boor P, Combe C, Eckardt KU, Eikefjord E, Garcia-Fernandez N, Golay X, Gordon I, Grenier N, Hockings PD, Jensen JD, Joles JA, Kalra PA, Krämer BK, Mark PB, Mendichovszky IA, Nikolic O, Odudu A, Ong ACM, Ortiz A, Pruijm M, Remuzzi G, Rørvik J, de Seigneux S, Simms RJ, Slatinska J, Summers P, Taal MW, Thoeny HC, Vallée JP, Wolf M, Caroli A, Sourbron S.

Nephrol Dial Transplant. 2018 Sep 1;33(suppl_2):ii4-ii14. doi: 10.1093/ndt/gfy152.

34.

Therapeutic potential of stromal cells of non-renal or renal origin in experimental chronic kidney disease.

Rota C, Morigi M, Cerullo D, Introna M, Colpani O, Corna D, Capelli C, Rabelink TJ, Leuning DG, Rottoli D, Benigni A, Zoja C, Remuzzi G.

Stem Cell Res Ther. 2018 Aug 14;9(1):220. doi: 10.1186/s13287-018-0960-8.

35.

SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy.

Cassis P, Locatelli M, Cerullo D, Corna D, Buelli S, Zanchi C, Villa S, Morigi M, Remuzzi G, Benigni A, Zoja C.

JCI Insight. 2018 Aug 9;3(15). pii: 98720. doi: 10.1172/jci.insight.98720. eCollection 2018 Aug 9.

36.

Engineered Kidney Tubules for Modeling Patient-Specific Diseases and Drug Discovery.

Benedetti V, Brizi V, Guida P, Tomasoni S, Ciampi O, Angeli E, Valbusa U, Benigni A, Remuzzi G, Xinaris C.

EBioMedicine. 2018 Jul;33:253-268. doi: 10.1016/j.ebiom.2018.06.005. Epub 2018 Jul 3.

37.

Quantitation of the monoclonal antibody Denosumab by bioassay and validated LC methods.

Perobelli RF, Xavier B, Silveira ARD, Remuzzi GL, Motta LGJ, Dalmora SL.

Int J Biol Macromol. 2018 Nov;119:96-104. doi: 10.1016/j.ijbiomac.2018.07.120. Epub 2018 Jul 23.

PMID:
30048724
38.

Outrageous prices of orphan drugs: a call for collaboration.

Luzzatto L, Hyry HI, Schieppati A, Costa E, Simoens S, Schaefer F, Roos JCP, Merlini G, Kääriäinen H, Garattini S, Hollak CE, Remuzzi G; Second Workshop on Orphan Drugs participants.

Lancet. 2018 Sep 1;392(10149):791-794. doi: 10.1016/S0140-6736(18)31069-9. Epub 2018 Jul 20. No abstract available.

PMID:
30037734
39.

Clinical Management of Chronic Kidney Disease Patients in Italy: Results from the IRIDE Study.

Cozzolino M, Bolasco P, Ronco C, Conte G, Menè P, Mereu MC, Di Luca M, Roccatello D, Rosati A, Jommi C, Costanzo AM, Gualberti G, di Luzio Paparatti U, Remuzzi G.

Nephron. 2018;140(1):39-47. doi: 10.1159/000490769. Epub 2018 Jul 17.

PMID:
30016767
40.

Toward longitudinal studies of hemodynamically induced vessel wall remodeling.

Bozzetto M, Brambilla P, Rota S, Ene-Iordache B, Sironi S, Remuzzi G, Remuzzi A.

Int J Artif Organs. 2018 Nov;41(11):714-722. doi: 10.1177/0391398818784207. Epub 2018 Jul 12.

PMID:
29998758
41.

ADAMTS13 Deficiency Shortens the Life Span of Mice With Experimental Diabetes.

Cassis P, Cerullo D, Zanchi C, Corna D, Lionetti V, Giordano F, Novelli R, Conti S, Casieri V, Matteucci M, Locatelli M, Taraboletti G, Villa S, Gastoldi S, Remuzzi G, Benigni A, Zoja C.

Diabetes. 2018 Oct;67(10):2069-2083. doi: 10.2337/db17-1508. Epub 2018 Jul 5.

42.

Long-Term Clinical and Immunological Profile of Kidney Transplant Patients Given Mesenchymal Stromal Cell Immunotherapy.

Perico N, Casiraghi F, Todeschini M, Cortinovis M, Gotti E, Portalupi V, Mister M, Gaspari F, Villa A, Fiori S, Introna M, Longhi E, Remuzzi G.

Front Immunol. 2018 Jun 14;9:1359. doi: 10.3389/fimmu.2018.01359. eCollection 2018.

43.

The role of B7-1 in proteinuria of glomerular origin.

Novelli R, Benigni A, Remuzzi G.

Nat Rev Nephrol. 2018 Sep;14(9):589-596. doi: 10.1038/s41581-018-0037-z. Review.

PMID:
29959373
44.

Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.

Noris M, Donadelli R, Remuzzi G.

Pediatr Nephrol. 2018 Jun 9. doi: 10.1007/s00467-018-3989-0. [Epub ahead of print] Review.

PMID:
29948306
45.

Disparities in Chronic Kidney Disease Prevalence among Males and Females in 195 Countries: Analysis of the Global Burden of Disease 2016 Study.

Bikbov B, Perico N, Remuzzi G; on behalf of the GBD Genitourinary Diseases Expert Group.

Nephron. 2018;139(4):313-318. doi: 10.1159/000489897. Epub 2018 May 23.

46.

Safety of Iohexol Administration to Measure Glomerular Filtration Rate in Different Patient Populations: A 25-Year Experience.

Gaspari F, Thakar S, Carrara F, Perna A, Trillini M, Aparicio MC, Diadei O, Ferrari S, Cannata A, Stucchi N, Ruggenenti P, Remuzzi G, Perico N.

Nephron. 2018;140(1):1-8. doi: 10.1159/000489898. Epub 2018 May 17.

PMID:
29772565
47.

A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes.

van Zuydam NR, Ahlqvist E, Sandholm N, Deshmukh H, Rayner NW, Abdalla M, Ladenvall C, Ziemek D, Fauman E, Robertson NR, McKeigue PM, Valo E, Forsblom C, Harjutsalo V; Finnish Diabetic Nephropathy Study (FinnDiane), Perna A, Rurali E, Marcovecchio ML, Igo RP Jr, Salem RM, Perico N, Lajer M, Käräjämäki A, Imamura M, Kubo M, Takahashi A, Sim X, Liu J, van Dam RM, Jiang G, Tam CHT, Luk AOY, Lee HM, Lim CKP, Szeto CC, So WY, Chan JCN; Hong Kong Diabetes Registry Theme-based Research Scheme Project Group, Ang SF, Dorajoo R, Wang L, Clara TSH, McKnight AJ, Duffy S; Warren 3 and Genetics of Kidneys in Diabetes (GoKinD) Study Group, Pezzolesi MG; GENIE (GEnetics of Nephropathy an International Effort) Consortium, Marre M, Gyorgy B, Hadjadj S, Hiraki LT; Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group, Ahluwalia TS, Almgren P, Schulz CA, Orho-Melander M, Linneberg A, Christensen C, Witte DR, Grarup N, Brandslund I, Melander O, Paterson AD, Tregouet D, Maxwell AP, Lim SC, Ma RCW, Tai ES, Maeda S, Lyssenko V, Tuomi T, Krolewski AS, Rich SS, Hirschhorn JN, Florez JC, Dunger D, Pedersen O, Hansen T, Rossing P, Remuzzi G; SUrrogate markers for Micro- and Macrovascular hard endpoints for Innovative diabetes Tools (SUMMIT) Consortium, Brosnan MJ, Palmer CNA, Groop PH, Colhoun HM, Groop LC, McCarthy MI.

Diabetes. 2018 Jul;67(7):1414-1427. doi: 10.2337/db17-0914. Epub 2018 Apr 27.

48.

Blood Pressure and Metabolic Effects of Acetyl-l-Carnitine in Type 2 Diabetes: DIABASI Randomized Controlled Trial.

Parvanova A, Trillini M, Podestà MA, Iliev IP, Aparicio C, Perna A, Peraro F, Rubis N, Gaspari F, Cannata A, Ferrari S, Bossi AC, Trevisan R, Parameswaran S, Chávez-Iñiguez JS, Masnic F, Seck SM, Jiamjariyaporn T, Cortinovis M, Perico L, Sharma K, Remuzzi G, Ruggenenti P, Warnock DG.

J Endocr Soc. 2018 Mar 22;2(5):420-436. doi: 10.1210/js.2017-00426. eCollection 2018 May 1.

49.

Chronic kidney disease in the global adult HIV-infected population: A systematic review and meta-analysis.

Ekrikpo UE, Kengne AP, Bello AK, Effa EE, Noubiap JJ, Salako BL, Rayner BL, Remuzzi G, Okpechi IG.

PLoS One. 2018 Apr 16;13(4):e0195443. doi: 10.1371/journal.pone.0195443. eCollection 2018. Review.

50.

The Cost of Patients with Chronic Kidney Failure Before Dialysis: Results from the IRIDE Observational Study.

Jommi C, Armeni P, Battista M, di Procolo P, Conte G, Ronco C, Cozzolino M, Costanzo AM, di Luzio Paparatti U, Concas G, Remuzzi G; IRIDE Study Group.

Pharmacoecon Open. 2018 Dec;2(4):459-467. doi: 10.1007/s41669-017-0062-z.

Supplemental Content

Loading ...
Support Center